Our study in an Asian series of triple-negative breast cancer patients demonstrated that up to 24.5% (27 of 110) women have germline mutations in BRCA1 (23 of 110) and BRCA2 (four of 110), and that the addition of negative estrogen-receptor status and PTEN loss improves the sensitivity of the Manchester Scoring method in our Asian cohort. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.